Is the price fair?
What NEO's price assumes
NeoGenomics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 1.28× revenue.
1.28
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 1.16
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 1.16
- EV / EBIToperating margin −8.9%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $1.45B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #7 of 29 by Smart Score